VANCOUVER, Feb. 13 /CNW/ - Protox Therapeutics Inc. (TSX: PRX), a leader
in advancing novel, targeted therapeutic proteins, today announced that data
from the completed Phase 1 clinical study testing PRX302 in patients with
locally recurrent prostate cancer following radiation failure will be
presented at the American Society of Clinical Oncology ("ASCO") Genitourinary
Cancer Symposium in San Francisco, California.
Scott Coffield, M.D., Principal Investigator from the lead site at Scott
and White Memorial Hospital, will deliver the presentation, entitled
"Intraprostatic Treatment of Patients with Locally Recurrent Prostate Cancer
with the PSA-Activated Protoxin PRX302" on Thursday, February 14, 2008 at the
San Francisco Marriott.
PRX302 is rationally designed to kill prostate cancer and hyperplastic
cells that over-produce the enzyme prostate specific antigen (PSA). A Phase 1
study has been completed and final results were released in November 2007
indicating that PRX302 is safe and well tolerated while demonstrating
encouraging signs of therapeutic activity. A Phase 2a clinical trial
evaluating PRX302 for the treatment of localized recurrent prostate cancer
following radiation failure has been initiated. The trial is designed to
determine the optimal injection regimen that provides the maximal therapeutic
benefit, while maintaining safety and tolerability of a single intra-prostatic
treatment of PRX302. By increasing the volume and/or number of deposits, it is
anticipated that the treatment effects of PRX302 may extend to larger volumes
of the prostate and, consequently, enhance its therapeutic activity.
Protox Therapeutics is a leader in advancing novel, targeted protein
therapeutics for the treatment of cancer and other proliferative diseases. Two
novel drug candidates derived from the company's INxin(TM) and PORxin(TM)
platforms are being developed in three clinical programs. A Phase 2a clinical
trial evaluating PRX321 (INxin) for the treatment of primary brain cancer has
been completed and the drug has received Fast Track Designation and Orphan
Drug Status from the US FDA. A Phase 2a clinical trial evaluating PRX302
(PORxin) for the treatment of localized prostate cancer has been initiated and
plans to commence a Phase 2 clinical trial for the treatment of benign
prostatic hyperplasia (enlarged prostate) are currently underway.
NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS
RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Protox'
current beliefs as well as assumptions made by and information currently
available to Protox and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Protox in its public securities filings; actual
events may differ materially from current expectations. Protox disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
For further information:
For further information: James Beesley, Director, Investor Relations,
Protox Therapeutics, (604) 484-0975, email@example.com; Michael
Moore, Investor Relations, Equicom Group, (416) 815-0700 x 241,